-
Product Insights
New![]()
Net Present Value Model: AIM ImmunoTech Inc’s Ampligen
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
AIMS AA REIT Solar PV Park
AIMS AA REIT Solar PV Park profile includes core details such as plant name, technology, capacity, status, plant proponents (owners, developers etc.), owner stakes etc as well as key operational data including generation, year online, decommissioning year, capital expenditure etc. Details on project specific contacts along with relevant news, deals and contracts are also provided through the plant profile. This is an on-demand report that will be delivered upon request. The report will be delivered within 1 business day of...
-
Product Insights
AIM – Makati Campus Renovation – Metro Manila
Equip yourself with the essential tools needed to make informed and profitable decisions with our AIM - Makati Campus Renovation - Metro Manila report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
AIM Group – Guangzhou Huadu Residential Facility – Guangdong
Equip yourself with the essential tools needed to make informed and profitable decisions with our AIM Group - Guangzhou Huadu Residential Facility - Guangdong report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
AIM RE Grp – Uplands Ridge Mixed-Use Community – Texas
Equip yourself with the essential tools needed to make informed and profitable decisions with our AIM RE Grp - Uplands Ridge Mixed-Use Community - Texas report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Company Profile
![]()
AIM ImmunoTech Inc – Company Profile
AIM ImmunoTech Inc (AIM ImmunoTech), formerly Hemispherx Biopharma Inc, is an immuno- pharma company. The company focuses on the research and development of therapeutics for the treatment of multiple types of cancers, viruses and immune-deficiency disorders. Its flagship products include Ampligen (rintatolimod) sterile solution which is indicated for the treatment of patients with chronic fatigue syndrome, and Alferon N Injection used for the treatment of refractory or recurrent external condylomata acuminate. The company’s pipeline products are intended to treat various...
Add to Basket -
Product Insights
Toxicology Tests – Germaine Laboratories Inc – AIM SCREEN
GlobalData, the industry analysis specialist, has released its latest report: Toxicology Tests - Germaine Laboratories Inc - AIM SCREEN. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ReS-19T in Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ReS-19T in Alzheimer's Disease Drug Details: ReS-19T is under development for the treatment of Alzheimer's...
-
Product Insights
New![]()
Net Present Value Model: Aldeyra Therapeutics Inc’s Reproxalap
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine For Grass Pollen Allergy And House Dust Mite Allergy in House Dust Mite Allergy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Vaccine For Grass Pollen Allergy And House Dust Mite Allergy in House Dust Mite AllergyDrug Details:Vaccine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NP-001 in Primary Progressive Multiple Sclerosis (PPMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.NP-001 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details:NP-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NP-001 in Huntington Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NP-001 in Huntington DiseaseDrug Details:NP-001 is under development for the treatment of amyotrophic lateral sclerosis (ALS),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NP-001 in Muscular Dystrophy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NP-001 in Muscular DystrophyDrug Details:NP-001 is under development for the treatment of amyotrophic lateral sclerosis (ALS),...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NP-001 in Frontotemporal Dementia (FTD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NP-001 in Frontotemporal Dementia (FTD)Drug Details:NP-001 is under development for the treatment of amyotrophic lateral sclerosis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Entolimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Entolimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Drug Details:Entolimod (CBLB-502) is under development for...
-
Sector Analysis
NewMadagascar Telecom Operators Country Intelligence Report
Madagascar Telecom Operators Country Intelligence Report The total telecom service revenue in Madagascar will increase at a CAGR of more than 6%, during 2023-2028, primarily supported by contributions from the mobile data service segment. The approval of $100 million credit for the Development Policy Operation (DPO) project aimed at strengthening governance frameworks in the telecom, energy, and mining sectors, the ongoing 5G trials, and ongoing subsea cable deployment in the country will be the market drivers. Madagascar Telecom Services Market...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Metenkefalin in Kaposi Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Metenkefalin in Kaposi SarcomaDrug Details: IRT-101 (methionine-enkephalin) is under development for the treatment of pancreatic cancer,...
-
Sector Analysis
NewSaudi Arabia Statutory and Private Employee Benefits, 2023 Update
The report provides in-depth industry analysis, information, and insights of the employee benefits in Saudi Arabia, including an overview of the state and compulsory benefits in Saudi Arabia, detailed information about the private benefits in Saudi Arabia, insights on various central institutions responsible for the administration of the different branches of social security and the regulatory framework of the employee benefits in Saudi Arabia. The Kingdom of Saudi Arabia has an extensive social security system, which aims to provide every...
-
Sector Analysis
NewFinancial Services (Payments) Sports Sponsorship Landscape – Analysing Biggest Brands and Spenders, Venue Rights, Deals and Case Studies
Financial Services (Payments) Sports Sponsorship Landscape Report Overview There are 1385 deals between sports rights holders and the Financial Services (FS)-payment sector, with these deals estimated annual worth to be $2.5 billion. Sports sponsorship grants financial services firms the opportunity to establish profound connections with expansive audiences and elevate their brand perception and value to new heights. Payments sector companies strategically target branding and activation rights in partnership with sports properties, aiming to attain prolonged exposure and enhance brand recognition,...
-
Sector Analysis
NewColombia Telecom Operators Country Intelligence Report
Colombia Telecom Operators Country Intelligence Report The total telecom and pay-TV service revenue in Colombia was $7.27 billion in 2022 and will increase at a CAGR of less than 0.5%, during 2022-2027, primarily supported by contributions from mobile data and fixed broadband service segments. This growth will also be driven by the government’s internet access program aimed at providing free internet connectivity to schools and expansion of broadband connectivity to remote areas of the country and the regulatory agenda 2023-2024...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.